Precision Gene Editing Applied to Small Molecule Drug Discovery

Light Horse is a small molecule drug discovery company that is leading the way in a “function first” approach applying proprietary precision gene editing and target agnostic functional screens to discover novel functionally critical targets. With our advanced platform, we are identifying cryptic, chemically accessible functional domains within biologic targets that form the root causes of disabling and life-threatening diseases, for which we then identify small molecule drugs to disrupt the disease process. Our initial focus addresses high-value, historically challenging oncology targets with the opportunity to apply the technology to other therapeutic areas in the future.